 Kenneth Malcolm
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium abscessus | 10 | 2025 | 107 | 4.030 |
Why?
| | Mycobacterium Infections, Nontuberculous | 15 | 2025 | 352 | 3.090 |
Why?
| | Neutrophils | 30 | 2025 | 1207 | 2.890 |
Why?
| | Host-Pathogen Interactions | 4 | 2025 | 351 | 1.830 |
Why?
| | Cystic Fibrosis | 15 | 2025 | 1053 | 1.660 |
Why?
| | Phagocytosis | 7 | 2025 | 362 | 1.110 |
Why?
| | Azithromycin | 4 | 2020 | 93 | 0.900 |
Why?
| | Immunity, Humoral | 1 | 2025 | 118 | 0.880 |
Why?
| | Interferons | 2 | 2016 | 193 | 0.800 |
Why?
| | Lipopolysaccharides | 11 | 2025 | 877 | 0.790 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 2537 | 0.730 |
Why?
| | Immunity, Innate | 3 | 2025 | 803 | 0.680 |
Why?
| | Klebsiella pneumoniae | 2 | 2018 | 42 | 0.630 |
Why?
| | Pseudomonas | 1 | 2018 | 28 | 0.620 |
Why?
| | Pseudomonas aeruginosa | 8 | 2022 | 347 | 0.590 |
Why?
| | Fomites | 1 | 2017 | 6 | 0.570 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 220 | 0.560 |
Why?
| | Nontuberculous Mycobacteria | 7 | 2025 | 203 | 0.550 |
Why?
| | Anti-Bacterial Agents | 11 | 2024 | 1702 | 0.550 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2004 | 311 | 0.420 |
Why?
| | Pseudomonas Infections | 5 | 2022 | 221 | 0.410 |
Why?
| | Neutrophil Activation | 1 | 2013 | 79 | 0.400 |
Why?
| | Reactive Oxygen Species | 4 | 2020 | 595 | 0.400 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.400 |
Why?
| | Staphylococcus aureus | 3 | 2015 | 434 | 0.380 |
Why?
| | Mycobacterium | 1 | 2013 | 106 | 0.370 |
Why?
| | Superoxides | 5 | 2018 | 201 | 0.360 |
Why?
| | Bacteria | 1 | 2018 | 812 | 0.360 |
Why?
| | Sputum | 5 | 2025 | 301 | 0.340 |
Why?
| | Microbial Viability | 3 | 2018 | 83 | 0.320 |
Why?
| | Immunoglobulin G | 2 | 2025 | 848 | 0.320 |
Why?
| | Biofilms | 5 | 2014 | 243 | 0.300 |
Why?
| | Extracellular Traps | 2 | 2018 | 46 | 0.280 |
Why?
| | Immunoglobulin M | 2 | 2025 | 276 | 0.260 |
Why?
| | Interleukin-8 | 3 | 2020 | 262 | 0.260 |
Why?
| | Humans | 44 | 2025 | 129248 | 0.260 |
Why?
| | Mannose-Binding Lectin | 1 | 2025 | 23 | 0.240 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1688 | 0.230 |
Why?
| | Extracellular Space | 2 | 2018 | 120 | 0.230 |
Why?
| | Cell Separation | 3 | 2016 | 316 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2002 | 756 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2025 | 137 | 0.220 |
Why?
| | Complement C3 | 1 | 2025 | 208 | 0.220 |
Why?
| | Tobramycin | 4 | 2016 | 51 | 0.210 |
Why?
| | Toll-Like Receptors | 3 | 2017 | 179 | 0.200 |
Why?
| | Cytokines | 8 | 2018 | 2013 | 0.200 |
Why?
| | GTP-Binding Proteins | 1 | 2003 | 158 | 0.200 |
Why?
| | Antimalarials | 1 | 2022 | 30 | 0.190 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 7 | 2011 | 275 | 0.190 |
Why?
| | Complement Activation | 1 | 2025 | 381 | 0.190 |
Why?
| | Primary Cell Culture | 2 | 2020 | 160 | 0.190 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 129 | 0.190 |
Why?
| | Case-Control Studies | 3 | 2020 | 3377 | 0.190 |
Why?
| | Pneumonia, Bacterial | 3 | 2013 | 115 | 0.180 |
Why?
| | Bacteriophages | 1 | 2022 | 86 | 0.180 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 23 | 0.170 |
Why?
| | RNA Splicing | 2 | 2023 | 260 | 0.170 |
Why?
| | Chloroquine | 1 | 2020 | 51 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4057 | 0.160 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 309 | 0.160 |
Why?
| | Sirolimus | 1 | 2020 | 266 | 0.150 |
Why?
| | Intracellular Space | 1 | 2018 | 69 | 0.140 |
Why?
| | Autophagy | 1 | 2020 | 266 | 0.140 |
Why?
| | Lung | 9 | 2024 | 3926 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 399 | 0.140 |
Why?
| | Respiratory System | 1 | 2018 | 154 | 0.140 |
Why?
| | Aztreonam | 1 | 2016 | 10 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2003 | 712 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 592 | 0.130 |
Why?
| | Signal Transduction | 3 | 2020 | 4926 | 0.130 |
Why?
| | Mice | 14 | 2024 | 16915 | 0.130 |
Why?
| | Survival Analysis | 2 | 2016 | 1269 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 400 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 216 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 854 | 0.120 |
Why?
| | Interferon-alpha | 1 | 2016 | 194 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2022 | 2703 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 347 | 0.120 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2737 | 0.120 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2015 | 77 | 0.120 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2014 | 53 | 0.120 |
Why?
| | Cell Movement | 4 | 2013 | 944 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 545 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 44 | 0.110 |
Why?
| | Oxidants | 1 | 2014 | 109 | 0.110 |
Why?
| | Deoxyribonucleases | 2 | 2011 | 23 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 851 | 0.110 |
Why?
| | Phagocytes | 1 | 2014 | 97 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2014 | 137 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 77 | 0.110 |
Why?
| | Odds Ratio | 1 | 2016 | 1018 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2011 | 1202 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 354 | 0.100 |
Why?
| | Rhinitis | 1 | 2015 | 152 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 156 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 29 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1497 | 0.100 |
Why?
| | Sinusitis | 1 | 2015 | 210 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2015 | 497 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 4 | 0.090 |
Why?
| | Animals | 15 | 2024 | 35307 | 0.090 |
Why?
| | Macrophages | 4 | 2023 | 1484 | 0.090 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2011 | 7 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 235 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 274 | 0.090 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 259 | 0.090 |
Why?
| | Neutrophil Infiltration | 3 | 2013 | 105 | 0.090 |
Why?
| | Lipids | 1 | 2015 | 625 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 332 | 0.090 |
Why?
| | Actins | 3 | 2009 | 411 | 0.090 |
Why?
| | Chemokine CXCL5 | 1 | 2011 | 11 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 27 | 0.090 |
Why?
| | Male | 12 | 2025 | 63501 | 0.090 |
Why?
| | Interleukin-17 | 1 | 2011 | 108 | 0.090 |
Why?
| | Biomarkers | 4 | 2025 | 3966 | 0.080 |
Why?
| | Viruses | 1 | 2011 | 100 | 0.080 |
Why?
| | Species Specificity | 1 | 2011 | 574 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 509 | 0.080 |
Why?
| | Burns | 1 | 2013 | 286 | 0.080 |
Why?
| | Retroviridae | 1 | 2008 | 99 | 0.080 |
Why?
| | Female | 11 | 2025 | 68543 | 0.070 |
Why?
| | Prospective Studies | 4 | 2025 | 7121 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 877 | 0.070 |
Why?
| | Peptides | 2 | 2011 | 923 | 0.070 |
Why?
| | cdc42 GTP-Binding Protein | 2 | 2006 | 23 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 400 | 0.070 |
Why?
| | Transgenes | 1 | 2008 | 177 | 0.070 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 67 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2016 | 10199 | 0.070 |
Why?
| | Bone Marrow | 1 | 2008 | 271 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1095 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 901 | 0.070 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2007 | 43 | 0.070 |
Why?
| | Middle Aged | 4 | 2020 | 31087 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2014 | 476 | 0.070 |
Why?
| | Cohort Studies | 2 | 2020 | 5408 | 0.070 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 112 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 336 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2006 | 89 | 0.060 |
Why?
| | Inflammation | 5 | 2022 | 2737 | 0.060 |
Why?
| | Up-Regulation | 3 | 2006 | 839 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 42 | 0.060 |
Why?
| | Adult | 7 | 2025 | 35495 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 307 | 0.060 |
Why?
| | Toll-Like Receptor 4 | 2 | 2007 | 263 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 313 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1396 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 187 | 0.060 |
Why?
| | Transcription, Genetic | 4 | 2008 | 1416 | 0.060 |
Why?
| | Membrane Microdomains | 1 | 2004 | 33 | 0.060 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1040 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 27 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2011 | 505 | 0.060 |
Why?
| | Enzyme Precursors | 1 | 2003 | 14 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 70 | 0.060 |
Why?
| | NF-kappa B | 4 | 2013 | 665 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2004 | 83 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 12388 | 0.050 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 16 | 0.050 |
Why?
| | Zymosan | 1 | 2023 | 65 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 171 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2003 | 13 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Bacterial Load | 2 | 2015 | 66 | 0.050 |
Why?
| | eIF-2 Kinase | 1 | 2003 | 30 | 0.050 |
Why?
| | Escherichia coli | 1 | 2007 | 766 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 129 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2003 | 70 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 338 | 0.050 |
Why?
| | Enzyme Activation | 4 | 2008 | 812 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 9745 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.050 |
Why?
| | Toll-Like Receptor 2 | 1 | 2003 | 113 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2005 | 389 | 0.050 |
Why?
| | Interferon Type I | 1 | 2003 | 139 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 360 | 0.050 |
Why?
| | Gene Expression | 2 | 2008 | 1466 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2003 | 194 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2013 | 367 | 0.050 |
Why?
| | Ciprofloxacin | 2 | 2013 | 30 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 286 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 380 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2022 | 666 | 0.040 |
Why?
| | Trans-Activators | 1 | 2003 | 388 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 432 | 0.040 |
Why?
| | Apoptosis | 2 | 2008 | 2498 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 2871 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 317 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7055 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2002 | 455 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 6543 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 14 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 644 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2117 | 0.040 |
Why?
| | Chemokine CXCL1 | 2 | 2011 | 72 | 0.040 |
Why?
| | Cell Migration Inhibition | 2 | 2011 | 16 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 300 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2011 | 137 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 38 | 0.030 |
Why?
| | Imidazoles | 3 | 2002 | 234 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2011 | 5439 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 147 | 0.030 |
Why?
| | Aged | 2 | 2015 | 22032 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 941 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1446 | 0.030 |
Why?
| | Cathelicidins | 1 | 2015 | 37 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 393 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 216 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1584 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1946 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2002 | 3079 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2014 | 38 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 580 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1715 | 0.030 |
Why?
| | Enzyme Inhibitors | 3 | 2002 | 827 | 0.030 |
Why?
| | Gentamicins | 1 | 2015 | 54 | 0.030 |
Why?
| | NADPH Oxidases | 1 | 2014 | 108 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 71 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 175 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2011 | 1304 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1869 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 183 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 506 | 0.030 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2003 | 161 | 0.030 |
Why?
| | Chemokine CCL2 | 2 | 2003 | 118 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 192 | 0.020 |
Why?
| | Fibrinogen | 1 | 2013 | 163 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3710 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2013 | 326 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 316 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 235 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 370 | 0.020 |
Why?
| | Down-Regulation | 2 | 2006 | 636 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 175 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 2220 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 551 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 36 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 380 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 43 | 0.020 |
Why?
| | Epithelium, Corneal | 1 | 2011 | 40 | 0.020 |
Why?
| | Corneal Ulcer | 1 | 2011 | 16 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 591 | 0.020 |
Why?
| | Genome | 1 | 2013 | 277 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 947 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 91 | 0.020 |
Why?
| | Methacrylates | 1 | 2011 | 112 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2630 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 247 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 452 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3772 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 777 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2779 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4886 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 77 | 0.020 |
Why?
| | Pyridines | 2 | 2002 | 478 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4406 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 90 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 312 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2013 | 895 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2011 | 279 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 171 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 232 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2007 | 27 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 53 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 131 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 79 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2374 | 0.020 |
Why?
| | Child | 2 | 2020 | 20773 | 0.020 |
Why?
| | Keratinocytes | 1 | 2007 | 242 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2005 | 134 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 147 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 7 | 0.010 |
Why?
| | rac GTP-Binding Proteins | 1 | 2004 | 32 | 0.010 |
Why?
| | Vital Capacity | 1 | 2005 | 289 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 24 | 0.010 |
Why?
| | Syk Kinase | 1 | 2003 | 21 | 0.010 |
Why?
| | Anthracenes | 1 | 2003 | 31 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2004 | 79 | 0.010 |
Why?
| | rho GTP-Binding Proteins | 1 | 2004 | 61 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 506 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5045 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1204 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4076 | 0.010 |
Why?
| | Dexamethasone | 1 | 2005 | 350 | 0.010 |
Why?
| | Chemokines | 1 | 2004 | 226 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2004 | 302 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 510 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 97 | 0.010 |
Why?
| | Protein Phosphatase 2 | 1 | 2002 | 38 | 0.010 |
Why?
| | Cholesterol | 1 | 2004 | 412 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1288 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 2002 | 76 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 110 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 1074 | 0.010 |
Why?
| | Aminopyridines | 1 | 2002 | 97 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 621 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 136 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 480 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2002 | 88 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2008 | 1063 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 20303 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1887 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2003 | 442 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 768 | 0.010 |
Why?
| | Homeostasis | 1 | 2004 | 605 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1085 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2146 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2056 | 0.010 |
Why?
| | Proteome | 1 | 2002 | 438 | 0.010 |
Why?
|
|
Malcolm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|